Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia

References

• National Comprehensive Cancer Network (NCCN) Practice Guidelines (version 2.2011): Chronic myelogenous leukemia http://www.nccn.org/professionals/physician_gls/PDF/cmlpdf. Accessed October 10, 2010.
   Google Scholar
• O’BrienSGGuilhotFLarsonRAImatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med2003348994100412637609
   PubMed Web of Science ®Google Scholar
• DrukerBJGuilhotFO’BrienSGFive-year follow-up of patients receiving imatinib for chronic myeloid leukemiaN Engl J Med20063552408241717151364
   PubMed Web of Science ®Google Scholar
• HochhausADrukerBJLarsonRAIRIS 6-year follow-up: Sustained survival and declining annual rate of transformation in patiens with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinibBlood200711015
   Web of Science ®Google Scholar
• DeiningerMO’BrienSGGuilhotFInternational Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinibBlood20091141126
   Web of Science ®Google Scholar
• HamdanMYSLOliveriaSCampbellUDiscontinuation and dose modfication of imatinib in clinical practiceJ Clin Oncol2007257045
   Web of Science ®Google Scholar
• JabbourEKantarjianHMJonesDImatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapyBlood20091132154216019060245
   PubMed Web of Science ®Google Scholar
• KantarjianHMGilesFGattermannNNilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intoleranceBlood20071103540354617715389
   PubMed Web of Science ®Google Scholar
• Le CoutrePOttmannOGGilesFNilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemiaBlood20081111834183918048643
   PubMed Web of Science ®Google Scholar
• HochhausAKantarjianHMBaccaraniMDasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyBlood20071092303230917138817
   PubMed Web of Science ®Google Scholar
• GuilhotFApperleyJKimDWDasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phaseBlood20071094143415017264298
   PubMed Web of Science ®Google Scholar
• CortesJKantarjianHMKimDWEfficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinibBlood20081121098
   Web of Science ®Google Scholar
• HochhausABaccaraniMDeiningerMDasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibLeukemia2008221200120618401416
   PubMed Web of Science ®Google Scholar
• Gambacorti-PasseriniCPoglianiEMBaccaraniMBosutinib (SKI-606) demonstrates clinical activity and is well tolerated in patients with AP and BP CML and Ph+ ALLBlood2008112110118559671
   PubMed Web of Science ®Google Scholar
• KurzrockRGuttermanJUTalpazMThe molecular genetics of Philadelphia chromosome-positive leukemiasN Engl J Med19883199909983047582
   PubMed Web of Science ®Google Scholar
• FaderlSJehaSKantarjianHMThe biology and therapy of adult acute lymphoblastic leukemiaCancer2003981337135414508819
   PubMed Web of Science ®Google Scholar
• DrukerBJTalpazMRestaDJEfficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemiaN Engl J Med20013441031103711287972
   PubMed Web of Science ®Google Scholar
• DrukerBJLydonNBLessons learned from the development of an ABL tyrosine kinase inhibitor for chronic myelogenous leukemiaJ Clin Invest20001053710619854
   PubMed Web of Science ®Google Scholar
• Cowan-JacobSWGuezVFendrichGImatinib (STI571) resistance in chronic myelogenous leukemia: Molecular basis of the underlying mechanisms and potential strategies for treatmentMini Rev Med Chem2004428529915032675
   PubMed Web of Science ®Google Scholar
• WeisbergEManleyPWBreitensteinWCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-AblCancer Cell2005712914115710326
   PubMed Web of Science ®Google Scholar
• Quintas-CardamaAKantarjianHCortesJFlying under the radar: The new wave of BCR-ABL inhibitorsNat Rev Drug Discov2007683483817853901
   PubMed Web of Science ®Google Scholar
• ManleyPWDrueckesPFendrichGExtended kinase profile and properties of the protein kinase inhibitor nilotinibBiochim Biophys Acta2010180444545319922818
   PubMed Web of Science ®Google Scholar
• WarmuthMDanhauser-RiedlSHallekMMolecular pathogenesis of chronic myeloid leukemia: Implications for new therapeutic strategiesAnn Hematol199978496410089019
   PubMed Web of Science ®Google Scholar
• HuYLiuYPelletierSRequirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemiaNat Genet20043645346115098032
   PubMed Web of Science ®Google Scholar
• MahonFXHayetteSLagardeVEvidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpressionCancer Res2008689809981619047160
   PubMed Web of Science ®Google Scholar
• SaijoKSchmedtCSuIHEssential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell developmentNat Immunol2003427427912563261
   PubMed Web of Science ®Google Scholar
• HibbsMLTarlintonDMArmesJMultiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune diseaseCell1995833013117585947
   PubMed Web of Science ®Google Scholar
• HarderKWQuiliciCNaikEPerturbed myelo/erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatases SHP-1 and SHIP-1Blood20041043901391015339845
   PubMed Web of Science ®Google Scholar
• CarpiucKTSnedecorSJLiouSYBottemanMFIncidence of grade 3/4 adverse events in imatinib resistant/intolerant chronic phase CML (CP-CML): A comparison of nilotinib and dasatinibPresented at the 2007 ASCO annual meetingChicago, ILMay 31–June 3, 2007
   Google Scholar
• SnedecorSJCarpiucKTLiouSYBottemanMFGrade 3/4 adverse events (AEs) of second generation tyrosine kinase inhibitors (TKIs) for imatinib resistant/intolerant patients in accelerated phase CML (AP-CML)J Clin Oncol200725 Abstr 17525.
   Web of Science ®Google Scholar
• BaccaraniMCortesJPaneFChronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNetJ Clin Oncol2009276041605119884523
   PubMed Web of Science ®Google Scholar
• CortesJQuintas-CardamaAKantarjianHMMonitoring molecular response in chronic myeloid leukemiaCancer10192010 [Epub ahead of print].
   Google Scholar
• LandstromAPKetterlingRPKnudsonRAUtility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemiaLeuk Lymphoma2006472055206117071476
   PubMed Web of Science ®Google Scholar
• Douet-GuilbertNMorelFLe CharpentierTInterphase FISH for follow-up of Philadelphia chromosome-positive chronic myeloid leukemia treatmentAnticancer Res2004242535253915330210
   PubMed Web of Science ®Google Scholar
• SeongDCKantarjianHMRoJYHypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatmentBlood199586234323497662980
   PubMed Web of Science ®Google Scholar
• HughesTPKaedaJBranfordSFrequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemiaN Engl J Med20033491423143214534335
   PubMed Web of Science ®Google Scholar
• HughesTDeiningerMHochhausAMonitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsBlood2006108283716522812
   PubMed Web of Science ®Google Scholar
• BranfordSCrossNCHochhausARationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemiaLeukemia2006201925193016990771
   PubMed Web of Science ®Google Scholar
• CrossNCStandardisation of molecular monitoring for chronic myeloid leukaemiaBest Pract Res Clin Haematol20092235536519959086
   PubMed Web of Science ®Google Scholar
• Quintas-CardamaAKantarjianHJonesDDelayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapyBlood20091136315632119369233
   PubMed Web of Science ®Google Scholar
• KantarjianHO’BrienSJabbourEDifferent definitions of progression-free survival (PFS) and event-free survival (EFS) may result in perceived but not real differences in long-term outcome when comparing trials in chronic myeloid leukemia (CML)Blood2010116672
   Web of Science ®Google Scholar
• SaglioGKimDWIssaragrisilSNilotinib versus imatinib for newly diagnosed chronic myeloid leukemiaN Engl J Med20103622251225920525993
   PubMed Web of Science ®Google Scholar
• RostiGPalandriFCastagnettiFNilotinib for the frontline treatment of Ph(+) chronic myeloid leukemiaBlood20091144933493819822896
   PubMed Web of Science ®Google Scholar
• BaccaraniMSaglioGGoldmanJEvolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNetBlood20061081809182016709930
   PubMed Web of Science ®Google Scholar
• RostiGCastagnettiFPalandriFNilotinib 800 mg daily as frontline therapy of Ph+ chronic myeloid leukemia: Dose delivered and safety profile for the GIMEMA CML working partyBlood20091142205
   Web of Science ®Google Scholar
• CortesJEJonesDO’BrienSNilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phaseJ Clin Oncol20102839239720008621
   PubMed Web of Science ®Google Scholar
• CortesJBaccaraniMGuilhotFA phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1 year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) studyBlood2008112335
   Web of Science ®Google Scholar
• ConneallyESwordsRTGilesFJNilotinib 300 mg twice daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: Updated results of the ICORG 0802 phase 2 study with analysis of the GeneXpert system versus IS BCR-ABL RQ PCRBlood20101163427
   Web of Science ®Google Scholar
• SokalJECoxEBBaccaraniMPrognostic discrimination in “good-risk” chronic granulocytic leukemiaBlood1984637897996584184
   PubMed Web of Science ®Google Scholar
• HughesTPHochhausASaglioGENESTnd update: Continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)Blood2010110207
   Google Scholar
• KantarjianHShahNPHochhausADasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med20103622260227020525995
   PubMed Web of Science ®Google Scholar
• ShahNKantarjianHHochhausADasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18 month follow-upBlood2010116206
   Web of Science ®Google Scholar
• Gambacorti-PasseriniCKimDWKantarjianHAn ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemiaBlood2010116208
   Google Scholar
• NoensLvan LierdeMADe BockRPrevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO studyBlood20091135401541119349618
   PubMed Web of Science ®Google Scholar
• DarkowTHenkHJThomasSKTreatment interruptions and non-adherence with imatinib and associated healthcare costs: A retrospective analysis among managed care patients with chronic myelogenous leukaemiaPharmacoeconomics20072548149617523753
   PubMed Web of Science ®Google Scholar
• MarinDBazeosAMahonFXAdherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinibJ Clin Oncol2010282381238820385986
   PubMed Web of Science ®Google Scholar
• DeremerDLUstunCNatarajanKNilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemiaClin Ther2008301956197519108785
   PubMed Web of Science ®Google Scholar
• ApperleyJFPart I: Mechanisms of resistance to imatinib in chronic myeloid leukaemiaLancet Oncol200781018102917976612
   PubMed Web of Science ®Google Scholar
• PressRDWillisSGLaudadioJDetermining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinibBlood20091142598260519625707
   PubMed Web of Science ®Google Scholar
• SoveriniSColarossiSGnaniAContribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid LeukemiaClin Cancer Res2006127374737917189410
   PubMed Web of Science ®Google Scholar
• ShahNPNicollJMNagarBMultiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemiaCancer Cell2002211712512204532
   PubMed Web of Science ®Google Scholar
• DeiningerMBuchdungerEDrukerBJThe development of imatinib as a therapeutic agent for chronic myeloid leukemiaBlood20051052640265315618470
   PubMed Web of Science ®Google Scholar
• JabbourEBranfordSSaglioGPractical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemiaCancer11292010 [Epub ahead of print].
   Google Scholar
• WeisbergEManleyPMestanJAMN107 (nilotinib): A novel and selective inhibitor of BCR-ABLBr J Cancer2006941765176916721371
   PubMed Web of Science ®Google Scholar
• RedaelliSPiazzaRRostagnoRActivity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutantsJ Clin Oncol20092746947119075254
   PubMed Web of Science ®Google Scholar
• HughesTSaglioGBranfordSImpact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phaseJ Clin Oncol2009274204421019652056
   PubMed Web of Science ®Google Scholar
• BradeenHAEideCAO’HareTComparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: High efficacy of drug combinationsBlood20061082332233816772610
   PubMed Web of Science ®Google Scholar
• RayACowan-JacobSWManleyPWIdentification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis studyBlood20071095011501517303698
   PubMed Web of Science ®Google Scholar
• KantarjianHMJabbourEGilesFPrognostic factors for progression free survival in patients with imatinib resistnat or intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib based on 24 month dataBlood20091143298
   Web of Science ®Google Scholar
• O’HareTShakespeareWCZhuXAP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceCancer Cell20091640141219878872
   PubMed Web of Science ®Google Scholar
• Cortes-FrancoJKhouryHJNicoliniFESafety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the bcr- abl T315I mutation – results of an ongoing multicenter Phase 2/3 studyBlood2009114644
   Web of Science ®Google Scholar
• BranfordSMeloJVHughesTPSelecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: Does the BCR-ABL mutation status really matter?Blood20091145426543519880502
   PubMed Web of Science ®Google Scholar
• Von BubnoffNManleyPWMestanJBcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)Blood20061081328133316614241
   PubMed Web of Science ®Google Scholar
• CortesJJabbourEKantarjianHDynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitorsBlood20071104005401117785585
   PubMed Web of Science ®Google Scholar
• JabbourEKantarjianHJonesDFrequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylateLeukemia2006201767177316855631
   PubMed Web of Science ®Google Scholar
• O’HareTEideCADeiningerMWBcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemiaBlood20071102242224917496200
   PubMed Web of Science ®Google Scholar
• BrecciaMCannellaLNanniMNilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapyActa Haematol200711816216417890849
   PubMed Web of Science ®Google Scholar
• SoveriniSColarossiSGnaniAResistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domainHaematologica20079240140417339191
   PubMed Web of Science ®Google Scholar
• HochhausASaglioGLarsonRNilotinib lowers the incidence of BCR-ABL mutations and improves the molecular response kinetics compared with imatinib in patients (Pts) with newly diagnosed chronic myeloid leukemia (CML)Blood2010116343120656929
   PubMed Web of Science ®Google Scholar
• EghtedarAKantarjianHJabbourEOutcome after failure to second generation tyrosine kinase inhibitors (TKI) treatment as frontline therapy for patients with chronic myeloid leukemia (CML) in chronic phase (CP)Blood2010116
   Google Scholar
• Package insertTasigna (nilotinib)East Hanover, NJNovartis Pharmaceuticals2010
   Google Scholar
• MauroMJDeiningerMWManagement of drug toxicities in chronic myeloid leukaemiaBest Pract Res Clin Haematol20092240942919959091
   PubMed Web of Science ®Google Scholar
• Quintas-CardamaAKantarjianHO’BrienSPleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failureJ Clin Oncol2007253908391417761974
   PubMed Web of Science ®Google Scholar
• CohenMHWilliamsGJohnsonJRApproval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemiaClin Cancer Res2002893594212006504
   PubMed Web of Science ®Google Scholar
• Quintas-CardamaAKantarjianHMMundenRPleural effusion in patient (pts) with chronic myelogenous leukemia (CML) treated with dasatinib after imatinib failureBlood2006108 Abstr 2164.
   PubMed Web of Science ®Google Scholar
• ShahNPKantarjianHMKimDWIntermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemiaJ Clin Oncol2008263204321218541900
   PubMed Web of Science ®Google Scholar
• LombardoLJLeeFYChenPDiscovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assaysJ Med Chem2004476658666115615512
   PubMed Web of Science ®Google Scholar
• PietrasKSjoblomTRubinKPDGF receptors as cancer drug targetsCancer Cell2003343944312781361
   PubMed Web of Science ®Google Scholar
• BergeronAReaDLevyVLung abnormalities after dasatinib treatment for chronic myeloid leukemia: A case seriesAm J Respir Crit Care Med200717681481817600277
   PubMed Web of Science ®Google Scholar
• De LavalladeHPunnialingamSMilojkovicDPleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesisBr J Haematol200814174574718331365
   PubMed Web of Science ®Google Scholar
• LiptonJHSriharshaIBogomilskySPleural effusions in patients treated with dasatinib: Results from two institutions, risk factors, and managementJ Clin Oncol20072517503
   Web of Science ®Google Scholar
• CortesJRousselotPKimDWDasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisisBlood20071093207321317185463
   PubMed Web of Science ®Google Scholar
• KantarjianHMGilesFHochhausANilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated Phase II resultsJ Clin Oncol20081267010
   Google Scholar
• SantosFPKantarjianHFavaCClinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemiaBr J Haematol201015030331220553275
   PubMed Web of Science ®Google Scholar
• BacikJMazumdarMMurphyBAThe functional assessment of cancer therapy-BRM (FACT-BRM): A new tool for the assessment of quality of life in patients treated with biologic response modifiersQual Life Res20041313715415058795
   PubMed Web of Science ®Google Scholar
• HahnEAGlendenningGASorensenMVQuality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS StudyJ Clin Oncol2003212138214612775739
   PubMed Web of Science ®Google Scholar
• Pinilla-IbarzJCortesJMauroMJIntolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implicationsCancer1042010 [Epub ahead of print].
   Web of Science ®Google Scholar
• WilliamsLAAultPWangXSThe symptom burden of chronic myelogenous leukemia (CML)Blood20081122408
   Google Scholar
• DrukerBJTamuraSBuchdungerEEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cellsNat Med199625615668616716
   PubMed Web of Science ®Google Scholar
• KantarjianHTalpazMO’BrienSHigh-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemiaBlood20041032873287815070658
   PubMed Web of Science ®Google Scholar
• KantarjianHO’BrienSShanJCytogenetic and molecular responses and outcome in chronic myelogenous leukemia: Need for new response definitions?Cancer200811283784518085610
   PubMed Web of Science ®Google Scholar
• De LavalladeHApperleyJFKhorashadJSImatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysisJ Clin Oncol2008263358336318519952
   PubMed Web of Science ®Google Scholar
• CortesJTalpazMBixbyDA phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: Emerging safety and clinical response findingsBlood201011621020304810
   PubMed Web of Science ®Google Scholar
• CortesJPaquetteRTalpazMPreliminary clinical activity in a phase I trial of the BCR-ABL/IGF-1R/aurora kinase inhibitor XL228 in patients with Ph+ leukemias with either failure to multiple TKI therapies or with T315I mutationBlood2008 Abstr 3232.
   Web of Science ®Google Scholar
• BorthakurGKantarjianHDaleyGPilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapyCancer200610634635216342165
   PubMed Web of Science ®Google Scholar
• FiskusWPranpatMBaliPCombined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cellsBlood200610864565216537804
   PubMed Web of Science ®Google Scholar
• FiskusWWangYJoshiRCotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cellsClin Cancer Res2008146106611518829489
   PubMed Web of Science ®Google Scholar